Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis: Results of the Phase III OCARINA II Study
Administration of ocrelizumab (OCR) subcutaneously (SC) provides an alternative route of administration to the approved intravenous (IV) route. The OCARINA II Phase 3 study was conducted to assess whether OCR SC, at the selected 920 mg dose, offers a similar safety, tolerability, immunogenicity, and clinical profile to 600 mg OCR IV.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.